Effects of a newly synthesized antiulcer agent,
YJA20379-4, on gastric
proton pump (H+/K+-
ATPase) activity, Helicobacter pylori (H. pylori) growth, gastric acid secretion, and gastro-duodenal lesions, were examined in comparison with those of
omeprazole.
YJA20379-4 markedly inhibited the H+/K+-
ATPase activity in a concentration-dependent manner and the inhibitory effect was increased under a weak acidic condition; the IC50 values were 32 and 81 microM at pH 6.4 and 7.4, respectively. The inhibition was completely antagonized by 0.5 mM
dithiothreitol (DTT). In addition,
YJA20379-4 showed a significant anti-H. pylori activity determined by the
agar dilution method. The value of minimum inhibitory concentration (MIC, 3.9-11.7 microg/ml) was at least 3 times more potent than that of
omeprazole. In pylorus ligated rats,
YJA20379-4 inhibited basal gastric acid secretion when administered by the intraduodenal route (ED50: 23.6 mg/kg). In experimental
ulcer models,
YJA20379-4 administered by the oral route dose-dependently prevented the development of gastro-duodenal lesions in rats. Moreover, repeated administration of
YJA20379-4 promoted the healing of
gastric ulcers induced by
acetic acid. On the basis of the data obtained, it is suggested that
YJA20379-4 has a wide spectrum of antiulcer activities, and its mode of antiulcer actions is dependent on the inhibition of H+/K+-
ATPase activity and H. pylori growth and the enhancement of a mucosal defense. Thus,
YJA20379-4 might prove to be a beneficial
therapy for
gastritis and
peptic ulcer diseases.